Febuxostat Patent Expiration

Febuxostat is Used for managing hyperuricemia in patients with gout. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Uloric on Feb 13, 2009. 16 different companies have introduced drugs containing Febuxostat.


Febuxostat Patents

Given below is the list of patents protecting Febuxostat, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Uloric US8372872 Methods for concomitant treatment of theophylline and febuxostat Sep 08, 2031 Takeda Pharms Usa
Uloric US9107912 Methods for concomitant treatment of theophylline and febuxostat Sep 08, 2031 Takeda Pharms Usa
Uloric US7361676 Solid preparation containing single crystal form Mar 08, 2024

(Expired)

Takeda Pharms Usa
Uloric US6225474 Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same Jun 18, 2019

(Expired)

Takeda Pharms Usa
Uloric US5614520 2-arylthiazole derivatives and pharmaceutical composition thereof Mar 25, 2019

(Expired)

Takeda Pharms Usa



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Febuxostat's patents.

Given below is the list recent legal activities going on the following patents of Febuxostat.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 20 Feb, 2023 US9107912
Payment of Maintenance Fee, 8th Year, Large Entity 12 Aug, 2020 US8372872
Payment of Maintenance Fee, 12th Year, Large Entity 01 Oct, 2019 US7361676(Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 18 Feb, 2019 US9107912
Change in Power of Attorney (May Include Associate POA) 30 Jan, 2019 US9107912
Email Notification 30 Jan, 2019 US9107912
Correspondence Address Change 29 Jan, 2019 US9107912
Change in Power of Attorney (May Include Associate POA) 10 Sep, 2018 US8372872
Email Notification 10 Sep, 2018 US8372872
Correspondence Address Change 07 Sep, 2018 US8372872


Febuxostat's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Febuxostat Generics

Several generic applications have been filed for Febuxostat. The first generic version for Febuxostat was by Sun Pharmaceutical Industries Ltd and was approved on Jul 1, 2019. And the latest generic version is by Lupin Ltd and was approved on Jan 17, 2024.

Given below is the list of companies who have filed for Febuxostat generic.


1. ALEMBIC

Alembic Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Alembic.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Prescription ORAL AB Jul 1, 2019
80MG tablet Prescription ORAL AB Jul 1, 2019


2. ALKEM LABS LTD

Alkem Laboratories Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Prescription ORAL AB Dec 7, 2021
80MG tablet Prescription ORAL AB Dec 7, 2021


3. AUROBINDO PHARMA LTD

Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Prescription ORAL AB Oct 25, 2023
80MG tablet Prescription ORAL AB Oct 25, 2023


4. DR REDDYS

Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Dr Reddys.

Strength Dosage Form Availability Application Pathway TE code Launch Date
80MG tablet Prescription ORAL AB Oct 22, 2020
40MG tablet Prescription ORAL AB Oct 22, 2020


5. HIKMA

Hikma Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Hikma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Prescription ORAL AB Oct 15, 2019
80MG tablet Prescription ORAL AB Oct 15, 2019


6. INDOCO

Indoco Remedies Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Indoco.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Prescription ORAL AB Dec 30, 2019
80MG tablet Prescription ORAL AB Dec 30, 2019


7. LUPIN LTD

Lupin Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Lupin Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Discontinued ORAL N/A Jan 17, 2024
80MG tablet Discontinued ORAL N/A Jan 17, 2024


8. MACLEODS PHARMS LTD

Macleods Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Prescription ORAL AB Sep 28, 2023
80MG tablet Prescription ORAL AB Sep 28, 2023


9. MSN

Msn Laboratories Private Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
80MG tablet Prescription ORAL BX Dec 30, 2019
40MG tablet Prescription ORAL BX Dec 30, 2019


10. MYLAN

Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Discontinued ORAL N/A Jul 1, 2019
80MG tablet Discontinued ORAL N/A Jul 1, 2019


11. PRINSTON INC

Prinston Pharmaceutical Inc has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Prinston Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Prescription ORAL AB Mar 28, 2022
80MG tablet Prescription ORAL AB Mar 28, 2022


12. SUN PHARM

Sun Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Sun Pharm.

Strength Dosage Form Availability Application Pathway TE code Launch Date
40MG tablet Prescription ORAL AB Jul 1, 2019
80MG tablet Prescription ORAL AB Jul 1, 2019


13. SUNSHINE

Sunshine Lake Pharma Co Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Sunshine.

Strength Dosage Form Availability Application Pathway TE code Launch Date
80MG tablet Prescription ORAL AB Jun 2, 2020
40MG tablet Prescription ORAL AB Jun 2, 2020


14. TORRENT

Torrent Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Torrent.

Strength Dosage Form Availability Application Pathway TE code Launch Date
80MG tablet Discontinued ORAL N/A Dec 19, 2023
40MG tablet Discontinued ORAL N/A Dec 19, 2023


15. ZYDUS LIFESCIENCES

Zydus Lifesciences Ltd has filed for 2 different strengths of generic version for Febuxostat. Given below are the details of the strengths of this generic introduced by Zydus Lifesciences.

Strength Dosage Form Availability Application Pathway TE code Launch Date
80MG tablet Prescription ORAL AB Jan 9, 2023
40MG tablet Prescription ORAL AB Jan 9, 2023